Investing Profile

David Schenkein

VCInvestor

General Partner at GV

gv.com/team/david-schenkein/Boston, Massachusetts

Your Intro Paths to David Schenkein

Signal uses Gmail to reveal intro paths. Email content is never read.

Networks David is a member of

Genentech Network

31 CONNECTIONS

GV Network

29 CONNECTIONS

Find David Schenkein on

Current Investing Position

GV (Google Ventures) General Partner

Investment Range

$250K - $50.0M

Sweet Spot

$25.0M

Investments On Record

Current Fund Size

$8B

David Schenkein is on these Sector & Stage Rankings

BioTech (Series B)Pharmaceuticals (Series B)BioTech (Series A)Pharmaceuticals (Series A)Boston / New England

David Schenkein's Investments On Record (18)

Company	StageDateRound Size	Total Raised
Cerevance	Series CMay 2026$20M Series BApr 2024$47M Series BFeb 2023$51M Series BApr 2020$65M	$180M
Co-investors: Kouki Harasaki (M12 - Microsoft's Venture Fund), Laurence Barker (SV Health Investors), Jason Lettmann (Morgenthaler Ventures), Bill Gates
Mestag Therapeutics	Series UnknownMar 2026$40M	$51M
Co-investors: Issi Rozen (GV (Google Ventures)), Houman Ashrafian (SV Health Investors)
EpiBiologics	Series BJan 2026$110M Series AJul 2023$23M	$200M
Co-investors: Anika Gupta (GV (Google Ventures)), Alexandra Cantley (Polaris Partners), Samuel Bjork (Digitalis Ventures), Laura Brass (MPM BioImpact), Alaa Halawa (Mubadala), Gaurav Aggarwal (Vivo Capital), Nisa Leung (Qiming Venture Partners)
Paradigm	Series BDec 2025$78M Series AJan 2023$200M	$320M
Co-investors: Niko Bonatsos (General Catalyst), Elena Viboch (General Catalyst), Hemant Taneja (General Catalyst), Ramnik Arora (FTX Ventures), Max Rimpel (Index Ventures), Bilal Zuberi (Lux Capital), Stephen Knight (F-Prime Capital Partners), Brett Cook (F-Prime Capital Partners), Jay Markowitz (ARCH Venture Partners), Robert Nelsen (ARCH Venture Partners), Alaa Halawa (Mubadala), Justin Kao (DFJ Growth), Jared Friedman (Israel Defense Forces), Scott Belsky (A24), Arash Ferdowsi, Eoghan McCabe, Karim Atiyeh, Balaji Srinivasan
Pelage Pharmaceuticals	Series BOct 2025$120M Series AAug 2024$14M Series AFeb 2024$17M	$150M
Co-investors: Richard Heyman (ARCH Venture Partners)
Treeline Biosciences	Series ASep 2025$200M Series AApr 2021$210M	$410M
Prime Medicine	Post Ipo EquityAug 2025$5M Series BJul 2021$200M Series AOct 2019$120M	$320M
Co-investors: Stephen Knight (F-Prime Capital Partners), Neil Sirni (Proximity Ventures), Stephen Francis (Arrive), Robert Nelsen (ARCH Venture Partners)
Rhygaze	Series AJan 2025$86M	$97M
Co-investors: Florian Müllershausen (Novartis Venture Fund), Daniela Couto (BGV (BioGeneration Ventures))